Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people take Mounjaro for at least 12 months, and many continue beyond that. There is no fixed end date set in the medicine's licence — how long you stay on it depends on how well it works for you, whether you experience side effects, and a clinical reassessment at six months if progress has been limited. Mounjaro (tirzepatide) is a prescription-only medicine, so the duration of your treatment is a decision made with your prescriber, not one you can set unilaterally. The NHS medicines page for tirzepatide confirms it is taken alongside a reduced-calorie diet and increased activity, and the treating clinician reviews ongoing suitability throughout.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro does not produce dramatic change in the first week or two. The treatment begins at 2.5 mg (a dose chosen specifically to let your body adjust rather than to drive weight loss immediately) and most people notice appetite changes gradually as the dose increases over the following months. The timeline for when Mounjaro starts to work varies between individuals, but the clinical trials ran for 72 weeks precisely because meaningful weight loss accumulates steadily rather than arriving all at once.
In SURMOUNT-1, the large randomised trial involving 2,539 adults with obesity, participants at the highest dose lost an average of around 20–21% of their body weight by week 72, roughly 18 months. That figure comes from continuous use over that period, not a short course. Significant weight loss is still occurring at six months for most people, and continues beyond it. Expecting a full result in eight weeks sets an unrealistic benchmark. If you want a broader picture of what the medicine involves, the tirzepatide overview covers its mechanism and UK licence in more detail.
One practical consequence of the gradual titration schedule: dose increases typically happen every four weeks, so reaching the maintenance dose that suits you can take several months on its own. The work of treatment is front-loaded in patience.
NICE's technology appraisal TA1026, which covers tirzepatide for weight management, sets one explicit checkpoint: if you have not lost at least 5% of your starting body weight after six months at the highest dose you can tolerate, continuing treatment should be reviewed with your clinician. That is a prompt to assess value for you specifically, not an instruction to stop.
Beyond that checkpoint, NICE does not impose a maximum duration in the way it does for semaglutide (Wegovy), where the recommendation explicitly states a two-year limit within specialist NHS services. For Mounjaro, the guidance is open-ended on length, making ongoing clinical review the deciding factor. Your prescriber looks at how much weight you have lost, whether that weight loss is translating into health improvements, and how well you are tolerating the treatment.
For anyone thinking about the question of staying on Mounjaro long-term, this distinction from semaglutide's rules is worth understanding. It does not mean indefinite treatment without review, it means the conversation with your clinician is the governing mechanism, not a hard calendar date. At nume, a prescriber reviews every repeat order individually before it is approved.
This is the question most people get to eventually. The honest answer, supported by trial data, is that stopping Mounjaro typically leads to some weight returning. The appetite-regulating and metabolic effects of tirzepatide are present while you are taking it; once treatment stops, the underlying biological drivers of weight (which are not fixed by a course of injections) reassert themselves.
That does not make the medicine ineffective. It reflects how obesity works as a condition. Many people and their clinicians decide to continue treatment for as long as the benefits outweigh any downsides, adjusting the dose where needed. Others use a period of treatment to establish new habits and then work with their prescriber on a careful, planned reduction. Neither path is automatically right. Context matters: how much weight you have lost, what health conditions prompted treatment, your own goals.
If cost is part of your thinking as you weigh up duration, the Mounjaro pricing page sets out what private treatment involves financially, which is worth reading alongside the clinical picture. Some people find that seeing the long-term commitment laid out clearly helps them plan properly rather than starting and stopping.
It is also worth noting that the question of how long Mounjaro can be taken safely has its own nuances around monitoring and tolerability, your prescriber will factor those in at each review.
There is no regulatory ceiling on duration written into Mounjaro's UK licence. The SmPC does not specify a maximum treatment period for weight management. What governs continued use in practice is ongoing clinical suitability: your prescriber, at each review, is asking whether you are still benefiting, whether any new health information changes the picture, and whether the dose remains appropriate.
Some people continue for years. Some take a planned break after achieving a stable weight. A question our prescribers hear regularly is whether it is safe to stay on the medicine for a long time, the answer is that the existing evidence (from the SURMOUNT programme and post-marketing surveillance) has not revealed safety signals that require a fixed stop date, but the monitoring infrastructure matters. That means not just buying more pens when the last one runs out, but having a prescriber who reads your record before each supply.
If you are already on treatment elsewhere and thinking about how long to continue for meaningful weight loss, transferring to a service that reviews your progress before each repeat is straightforward at nume. You bring evidence of your current treatment, and a prescriber reviews it the same day, a real clinician, not an automated approval system. Check whether you are eligible and start a conversation by visiting the treatment page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.